Ginkgo Bioworks (DNA) reported disappointing fourth-quarter results, with revenues reaching $33 million, a 24% decline year-over-year. The reported figures missed analyst estimates by more than $4 million, highlighting significant operational headwinds for the biotech firm. The company's Cell Engineering segment delivered $125 million in 2025 revenue, falling drastically short of the $1.1 billion projection originally set during its SPAC merger. In response to these challenges, management announced a major strategic pivot involving the sale of its Biosecurity business segment. Ginkgo plans to retain only a minority stake in the newly formed private entity as it seeks to restructure its struggling business model. This restructuring follows a period of sustained underperformance and a failure to meet the aggressive growth targets established during its public debut.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis